Engineering Processing Properties of Acetaminophen by Cosolvent Screening - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Engineering Processing Properties of Acetaminophen by Cosolvent Screening
The authors used common solvents to develop an initial solvent-screening method for laboratory-scale research to determine the solubility, polymorphism, and crystal properties of various active ingredients.


Pharmaceutical Technology
Volume 34, Issue 8, pp. 61-68

9. T. Lee and M.S. Lin, Cryst. Growth Des. 7 (9), 1803–1810 (2007).

10. T. Lee and S.T. Hung, Pharm. Technol. 32 (1), 76–95 (2008).

11. T. Lee, S.T. Hung, and C.S. Kuo, Pharm. Res. 23 (11), 2542–2555 (2006).

12. J.C. Burley et al., Eur. J. Pharm. Sci. 31 (5), 271–276 (2007).

13. N. Al-Zoubi, K. Kachrimanis, and S. Malamataris, Eur. J. Pharm. Sci. 17 (1–2), 13–21 (2002).

14. N. Al-Zoubi and S. Malamataris, Int. J. Pharm., 260 (1), 123–135 (2003).

15. P. Di Martino et al., J. Therm. Anal. 48 (3), 447–458 (1997).

16. M. L. Ramos, J.F. Tyson, and D.J. Curran, Anal. Chim. Acta 364 (1–3), 107–116 (1998).

17. R.G. Hollenbeck, J. Pharm. Sci. 69 (10), 1241–1242 (1980).

18. J.W. Mullin, "Solutions and Solubility," in Crystallization, (Butterworth Heinemann, Oxford, UK, 3rd ed., 1992), pp. 93–94.

19. S.H. Yalkowsky, "Solubilization by Cosolvents," in Solubility and Solubilization in Aqueous Media, (American Chemical Society and Oxford University Press, New York, 1999), pp. 180–235.

20. P.W.S. Heng and L.W. Chan, "Drug Substance and Excipient Characterization," in Handbook of Pharmaceutical Granulation Technology, D. M. Parikh, Ed. (Marcel Dekker, New York, 1st ed., 1997), p. 28.

21. M. Kitamura, M. Sugimoto, J. Cryst. Growth 257 (1–2), 177–184 (2003).

22. M. Lahav and L. Leiserowitz, Chem. Eng. Sci. 56 (7), 2245–2253 (2001).

23. B.F. Ruth, Ind. Eng. Chem. Res. 38 (6), 564–571 (1946).

24. E.W. Comings and T.K. Sherwood, Ind. Eng. Chem. Res. 26 (10), 1096–1098 (1934).

25. K. Miyanami, "Mixing," in Powder Technology Handbook, K. Gotoh, H. Masuda, and K. Higashitani, Eds. (Marcel Dekker, New York, 2nd ed., 1997), p. 618.

26. K. Umeya and I. Sekiguchi, J. Soc. Mater. Sci. Japan. 24 (262), 664–668 (1975).

27. B.E. Kurtz and A.J. Barduhn, Chem. Eng. Prog. 56 (1), 67–72 (1960).

28. T. Lee and C.S. Kuo, Pharm. Technol. 30 (3), 110–120 (2006).

29. W. Nernst, Z. Physik. Chem. 47 (1), 52–55 (1904).

30. E. Brunner, Z. Physik. Chem. 47 (1), 56–102 (1904).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here